Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study - Flisiak, R; Janczewska, E; Łucejko, M (J Viral Hepat, 2018)
et al.